keyword
MENU ▼
Read by QxMD icon Read
search

immunogenicity TNF

keyword
https://www.readbyqxmd.com/read/29341877/characterizing-the-effects-of-insertion-of-a-5-2%C3%A2-kb-region-of-a-vacv-genome-which-contains-known-immune-evasion-genes-on-mva-immunogenicity
#1
Melissa R Ryerson, Joanna L Shisler
Modified Vaccinia virus Ankara (MVA) is an attenuated Vaccinia virus (VACV) that is a popular vaccine vector candidate against many different pathogens. Its replication-restricted nature makes it a safe vaccine. However, higher doses or multiple boosts of MVA are necessary to elicit an immune response similar to wild-type VACV. Multiple strategies have been used to create modified MVA viruses that remain safe, but have increased immunogenicity. For example, one common strategy is to delete MVA immunomodulatory proteins in hopes of increasing the host immune response...
January 13, 2018: Virus Research
https://www.readbyqxmd.com/read/29340807/long-term-outcome-of-infliximab-optimization-for-overcoming-immunogenicity-in-patients-with-inflammatory-bowel-disease
#2
Konstantinos Papamichael, Ravy K Vajravelu, Mark T Osterman, Adam S Cheifetz
BACKGROUND: Preliminary data suggest that treatment optimization can reverse immunogenicity and regain response in patients with IBD and secondary loss of response (SLR) to anti-TNF therapy due to antidrug antibodies. However, data regarding the long-term outcome of these patients are scarce. AIMS: We aimed to investigate drug retention in IBD patients of whom infliximab was optimized to overcome immunogenicity and variables associated with drug retention. METHODS: This was a retrospective, multicenter study of consecutive IBD patients with antibodies to infliximab (ATI), based on either proactive or reactive therapeutic drug monitoring, who underwent infliximab optimization (increasing dose, shortening interval, adding an immunomodulator, or combination) to overcome immunogenicity from September 2012 to July 2015; they were followed through December 2015...
January 16, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29325166/drug-safety-and-immunogenicity-of-tumour-necrosis-factor-inhibitors-the-story-so-far
#3
Meghna Jani, William G Dixon, Hector Chinoy
TNF-α inhibitor (TNFi) therapies have transformed the treatment of several rheumatic musculoskeletal diseases. However, the majority of TNFi's are immunogenic and consequent anti-drug antibodies formation can impact on both treatment efficacy and safety. Several controversies exist in the area of immunogenicity of TNFis and drug safety. While anti-drug antibodies to TNFis have been described in association with infusion reactions; serious adverse events (AEs) such as thromboembolic events, lupus-like syndrome, paradoxical AEs, for example, vasculitis-like events and other autoimmune manifestations have also been reported...
January 8, 2018: Rheumatology
https://www.readbyqxmd.com/read/29313103/plant-synthetic-gp4-and-gp5-proteins-from-porcine-reproductive-and-respiratory-syndrome-virus-elicit-immune-responses-in-pigs
#4
Chul Han An, Salik Nazki, Sung-Chul Park, Yu Jeong Jeong, Ju Huck Lee, Su-Jin Park, Amina Khatun, Won-Il Kim, Youn-Il Park, Jae Cheol Jeong, Cha Young Kim
We demonstrated successful overexpression of porcine reproductive and respiratory syndrome virus (PRRSV)-derived GP4D and GP5D antigenic proteins in Arabidopsis. Pigs immunized with transgenic plants expressing GP4D and GP5D proteins generated both humoral and cellular immune responses to PRRSV. Porcine reproductive and respiratory syndrome virus (PRRSV) causes PRRS, the most economically significant disease affecting the swine industry worldwide. However, current commercial PRRSV vaccines (killed virus or modified live vaccines) show poor efficacy and safety due to concerns such as reversion of virus to wild type and lack of cross protection...
January 8, 2018: Planta
https://www.readbyqxmd.com/read/29287303/high-levels-of-dek-autoantibodies-in-sera-of-polyarticular-jia-patients-and-in-early-flare-following-cessation-of-anti-tnf-therapy
#5
Nirit Mor-Vaknin, Miguel Rivas, Maureen Legendre, Smriti Mohan, Ye Yuanfan, Theresa Mau, Anne Johnson, Bin Huang, Lili Zhao, Yukiko Kimura, Steven J Spalding, Paula W Morris, Beth S Gottlieb, Karen Onel, Judyann C Olson, Barbara S Edelheit, Michael Shishov, Lawrence K Jung, Elaine A Cassidy, Sampath Prahalad, Murray H Passo, Timothy Beukelman, Jay Mehta, Edward H Giannini, Barbara S Adams, Daniel J Lovell, David M Markovitz
OBJECTIVE: The nuclear oncoprotein DEK is an autoantigen associated with juvenile idiopathic arthritis (JIA), especially the oligoarticular subtype. DEK is a secreted chemoatactic factor. Abundant DEK and DEK autoantibodies are found in the inflamed JIA synovium. In screening sera samples from two different JIA patient cohorts for DEK autoantibodies, we now further characterize the nature of DEK autoantibodies. METHODS: DEK autoantibody levels were analyzed in sera from 33 JIA patients, 13 patients with other inflammatory conditions, and 11 healthy controls and 89 sera samples from JIA patients undergoing anti-TNF therapy...
December 29, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29258618/a-pilot-study-of-an-autologous-tumor-derived-autophagosome-vaccine-with-docetaxel-in-patients-with-stage-iv-non-small-cell-lung-cancer
#6
Rachel E Sanborn, Helen J Ross, Sandra Aung, Anupama Acheson, Tarsem Moudgil, Sachin Puri, Traci Hilton, Brenda Fisher, Todd Coffey, Christopher Paustian, Michael Neuberger, Edwin Walker, Hong-Ming Hu, Walter J Urba, Bernard A Fox
BACKGROUND: Tumor-derived autophagosome vaccines (DRibbles) have the potential to broaden immune response to poorly immunogenic tumors. METHODS: Autologous vaccine generated from tumor cells harvested from pleural effusions was administered to patients with advanced NSCLC with the objectives of assessing safety and immune response. Four patients were vaccinated and evaluable for immune response; each received two to four doses of vaccine. Study therapy included two cycles of docetaxel 75 mg/m2 on days 1 and 29 to treat the tumor, release hidden antigens and produce lymphopenia...
December 19, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29244149/subcutaneous-tocilizumab-in-rheumatoid-arthritis-findings-from-the-common-framework-phase-4-study-programme-tozura-conducted-in-22-countries
#7
Ernest Choy, Roberto Caporali, Ricardo Xavier, Bruno Fautrel, Raimón Sanmarti, Min Bao, Corrado Bernasconi, Attila Pethö-Schramm
Objectives: The aim of this pooled analysis of the TOZURA study programme was to evaluate the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs) in patients with moderate to severe RA who had an inadequate response to csDMARD or anti-TNF agent therapy or who were MTX naïve. Methods: TOZURA is a multinational, open-label, single-arm, common-framework, phase 4 study programme (11 protocols, 22 countries)...
December 13, 2017: Rheumatology
https://www.readbyqxmd.com/read/29235156/ifn-%C3%AE-against-the-38-kda-antigen-of-mycobacterium-tuberculosis-discriminates-pulmonary-tuberculosis-from-infection-and-infection-from-exposure-evidence-from-a-study-of-human-population-in-a-high-endemic-setting
#8
Fekadu Abebe, Mulugeta Belay, Mengistu Legesse
Mycobacterium tuberculosis (Mtb) 38-kDa antigen is an immunogenic lipoprotein that induces strong T-cell responses in experimental animals. However, there is limited information on the role of this antigen in human population. In this article, we present the dynamics of pro-inflammatory (IFN-γ and TNF-α) and anti-inflammatory cytokine (IL-10) against the 38 kDa in cohorts of pulmonary TB (PTB) patients, household contacts (HHCs), and community controls (CCs) in a high endemic setting. Whole blood assay was used to determine the levels of cytokines in 149 patients, 149 HHCs, and 68 CCs at baseline, 6 months, and 12 months...
December 13, 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/29223454/preparation-characterization-and-immunological-evaluation-of-alginate-nanoparticles-loaded-with-whole-inactivated-influenza-virus-dry-powder-formulation-for-nasal-immunization-in-rabbits
#9
Solmaz Dehghan, Masoumeh Tavassoti Kheiri, Khalil Abnous, Maryam Eskandari, Mohsen Tafaghodi
It has become important to explore more efficient and feasible influenza vaccines, since epidemics of influenza virus cause hundreds of thousands of deaths all around the world. Improving immunogenicity of parentral influenza vaccines has given rise to mucosal delivery routes. In this study, alginate nanoparticles (NPs) were efficiently synthetized by ionic gelation method and influenza virus and CpG ODN or Quillaja Saponin (QS) adjuvants were actively incorporated into alginate NPs. The prepared particles were evaluated for both humoral and cellular immune responses in rabbits' nostrils...
December 6, 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/29217118/checkpoints-in-tnf-induced-cell-death-implications-in-inflammation-and-cancer
#10
REVIEW
Alessandro Annibaldi, Pascal Meier
Tumor necrosis factor (TNF) is a proinflammatory cytokine that coordinates tissue homeostasis by regulating cytokine production, cell survival, and cell death. However, how life and death decisions are made in response to TNF is poorly understood. Many inflammatory pathologies are now recognized to be driven by aberrant TNF-induced cell death, which, in most circumstances, depends on the kinase Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). Recent advances have identified ubiquitin (Ub)-mediated phosphorylation of RIPK1 as belonging to crucial checkpoints for cell fate in inflammation and infection...
December 4, 2017: Trends in Molecular Medicine
https://www.readbyqxmd.com/read/29216514/modulation-of-in-vitro-phagocytic-uptake-and-immunogenicity-potential-of-modified-herceptin%C3%A2-conjugated-plga-peg-nanoparticles-for-drug-delivery
#11
Apurva Badkas, Evan Frank, Zilan Zhou, Mina Jafari, Harish Chandra, Vishnu Sriram, Joo-Youp Lee, Jagjit S Yadav
There is an increasing interest in engineered nanoparticle (NP) conjugates for targeted and controlled drug delivery. However, the practical applications of these NP delivery vehicles remain constrained because of their reactivity with the body's immune system defenses resulting in undesirable off-target effects. In this study, poly(D,L lactide-co-glycolide) (PLGA)-b-polyethylene glycol (PEG) NPs conjugated to different quantities of the commercial antibody Herceptin® meant to target HER2-positive breast cancer cells were studied for their immune cell uptake and immunogenic properties (using murine macrophages and human dendritic cells)...
December 4, 2017: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29209441/pcsk9-signaling-pathways-and-their-potential-importance-in-clinical-practice
#12
REVIEW
Michał Wiciński, Jarosław Żak, Bartosz Malinowski, Gabriela Popek, Grzegorz Grześk
In the following review, authors described the structure and biochemical pathways of PCSK9, its involvement in LDL metabolism, as well as significances of proprotein convertase subtilisin/kexin type 9 targeted treatment. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism. Transcription and translation of PCSK9 is controlled by different nuclear factors, such as, SREBP and HNF1α. This review focuses on interactions between PCSK9 and LDL receptor, VLDLR, ApoER2, CD36, CD81, and others...
December 2017: EPMA Journal
https://www.readbyqxmd.com/read/29185966/the-prevalence-and-clinical-effect-of-immunogenicity-of-tnf-%C3%AE-blockers-in-patients-with-axial-spondyloarthritis
#13
Gil Bornstein, Merav Lidar, Pnina Langevitz, Alexander Fardman, Ilan Ben-Zvi, Chagai Grossman
OBJECTIVES: To evaluate the prevalence of immunogenicity of TNF-α blockers in axial spondyloarthritis (SpA) patients and to assess the effect of immunogenicity on drug levels and clinical response. METHPDS: Patients with axial SpA treated with either infliximab (INF), adalimumab (ADA) or etanercept (ETN) were recruited to our observational cross-sectional study. Demographic and clinical data were collected and disease activity scores were assessed. Drug trough levels and anti-drug antibodies were measured in serum samples and collected before the next administration...
November 28, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29175315/flagellin-increases-death-receptor-mediated-cell-death-in-a-rip1-dependent-manner
#14
Dora Hancz, Aniko Szabo, Tamás Molnar, Zsofia Varga, Aniko Hancz, Andrea Gregus, Anne-Odile Hueber, Eva Rajnavolgyi, Gabor Koncz
Efficient adjuvants have the potential to trigger both innate and adaptive immune responses simultaneously. Flagellin is a unique pathogen-derived protein, which is recognized by pattern recognition receptors (PRRs) as well as by B-cell and T cell receptors thus providing an important link between innate and adaptive immunity. The aforementioned properties define flagellin as an optimal adjuvant. The induction of immunogenic cell death could be an additional expectation for adjuvants in the context of cancer immunotherapy due to their ability to activate dendritic cells (DC) to present tumor antigens through the engulfment of dying cells...
January 2018: Immunology Letters
https://www.readbyqxmd.com/read/29163540/local-high-dose-radiotherapy-induces-systemic-immunomodulating-effects-of-potential-therapeutic-relevance-in-oligometastatic-breast-cancer
#15
Elena Muraro, Carlo Furlan, Michele Avanzo, Debora Martorelli, Elisa Comaro, Aurora Rizzo, Damiana A Fae', Massimiliano Berretta, Loredana Militello, Alessandro Del Conte, Simon Spazzapan, Riccardo Dolcetti, Marco Trovo'
Local irradiation of cancer through radiotherapy can induce spontaneous regression of non-directly irradiated lesions, suggesting the involvement of systemic antitumor immune responses. In oligometastatic breast cancer (BC) patients, the use of stereotactic body radiotherapy (SBRT) favors the local control of treated lesions and may contribute to break local tolerance and release tumor-associated antigens (TAAs), improving host antitumor immunity. We performed a detailed immunomonitoring of BC patients undergoing SBRT to verify its ability to "switch on" the anti-tumor immunity both systemically, in peripheral blood, and locally, employing in vitro BC models...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29159802/adenovirus-vector-based-prime-boost-vaccination-via-heterologous-routes-induces-cervicovaginal-cd8-t-cell-responses-against-hpv16-oncoproteins
#16
Nicolas Çuburu, Selina Khan, Cynthia D Thompson, Rina Kim, Jort Vellinga, Roland Zahn, Douglas R Lowy, Gert Scheper, John T Schiller
Recent advances in immunotherapy against cancer underscore the importance of T lymphocytes and tumor microenvironment, but few vaccines targeting cancer have been approved likely due in part to the dearth of common tumor antigens, insufficient immunogenicity and the evolution of immune evasion mechanisms during the progression to malignancy. Human papillomaviruses (HPV) are the primary etiologic agents of cervical cancer and progression from persistent HPV-infection to cervical intraepithelial lesions and eventually cancer requires persistent expression of the oncoproteins E6 and E7...
November 21, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29158574/immunogenicity-and-loss-of-response-to-tnf-inhibitors-implications-for-rheumatoid-arthritis-treatment
#17
REVIEW
Joachim R Kalden, Hendrik Schulze-Koops
The availability of monoclonal antibodies has revolutionized the treatment of an increasingly broad spectrum of diseases. Inflammatory diseases are among those most widely treated with protein-based therapeutics, termed biologics. Following the first large-scale clinical trials with monoclonal antibodies performed in the 1990s by rheumatologists and clinical immunologists, the approval of these agents for use in daily clinical practice led to substantial progress in the treatment of rheumatic diseases. Despite this progress, however, only a proportion of patients achieve a long-term clinical response...
November 21, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29132705/il-17a-improves-the-efficacy-of-mesenchymal-stem%C3%A2-cells-in-ischemic-reperfusion-renal-injury%C3%A2-by%C3%A2-increasing-treg-percentages-by-the%C3%A2-cox-2-pge2%C3%A2-pathway
#18
Ming Bai, Li Zhang, Bo Fu, Jiuxu Bai, Yingjie Zhang, Guangyan Cai, Xueyuan Bai, Zhe Feng, Shiren Sun, Xiangmei Chen
Mesenchymal stem cells (MSCs) are effective for the management of experimental ischemia-reperfusion acute kidney injury (IRI-AKI). Immune modulation is one of the important mechanisms of MSCs treatment. Interleukin-17A (IL-17A) pretreated MSCs are more immunosuppressive with minimal changes in immunogenicity in vitro. Here, we demonstrated that administration of IL-17A-pretreated MSCs resulted in significantly lower acute tubular necrosis scores, serum creatinine, and BUN of mice with IRI-AKI, compared with the administration of MSCs...
November 11, 2017: Kidney International
https://www.readbyqxmd.com/read/29130994/enhancement-of-anti-leukemia-immunity-by-leukemia-derived-exosomes-via-downregulation-of-tgf-%C3%AE-1-expression
#19
Fang Huang, Jiangbo Wan, Weiwei Hu, Siguo Hao
BACKGROUND/AIMS: Minimal residual leukemia cells (MRLs) are difficult to eradicate through traditional treatment and therefore remain to be a major threat to the long-term survival of leukemia patients. Tumor-derived exosomes (TEXs), which carry tumor associated antigens (TAA), may be a potential cell-free tumor vaccine for the specific eradication of MRLs. However, TEXs are intended to be less immunogenic due to exosomal TGF-β1. To further optimize the efficacy of TEX-based vaccines, we investigated whether exosomes from TGF-β1 silenced leukemia cells (LEXTGF-β1si) had an increased potential to induce a specific antitumor effect compared with non-modified exosomes...
November 9, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29112895/polyactin-a-is-a-novel-and-potent-immunological-adjuvant-for-peptide-based-cancer-vaccine
#20
Wei Wang, Yanqin Li, Yawen Wang, Shuting Ren, Yiping Li, Bing Wang
Synthetic peptide cancer vaccines are poorly immunogenic sub-unit vaccines and thus essentially need adjuvants in their formulations to increase the efficacy by enhancing the peptide-specific immune response. However, aluminum-based compounds are almost dependent for clinical use at present. Therefore, the increasing use of peptide-based vaccines makes the need for novel and potent adjuvants. Polyactin A (PAA) has been used for the clinical treatment of impaired immunity in China for over 30years. To figure out the adjuvant effects of PAA for E75 peptide breast cancer vaccine (Her2 p369-p377), the generation of mature dendritic cells (DCs) from peripheral blood monocytes (PBMCs) cultured with PAA, IL-4 and TNF-α was assessed by morphologic features and the expressions of special surface markers using flow cytometry...
November 4, 2017: International Immunopharmacology
keyword
keyword
56251
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"